NextCell Pharma AB (STO:NXTCL)

NextCell Pharma AB Income Statement

Financials in millions SEK. Fiscal year is September - August.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Operating Revenue	10.94	10.66	10.11	5.59	3.91
Other Revenue	0.13	0.61	3.84	0.64	0.54
Revenue	11.06	11.28	13.96	6.23	4.46
Revenue Growth (YoY)	-1.90%	-19.18%	124.03%	39.82%	6.93%
Cost of Revenue	9.4	15.22	11	8.72	9.94
Gross Profit	1.67	-3.94	2.96	-2.49	-5.48
Selling, General & Admin	34.9	38.22	43.47	31.85	18.84
Other Operating Expenses	0.14	0.04	0.04	0.22	0.06
Operating Expenses	37.55	39.23	43.96	32.53	19.34
Operating Income	-35.89	-43.17	-41	-35.02	-24.82
Interest Expense	-0	-0	-0	-0.01	-0.01
Interest & Investment Income	0.75	1.21	1.19	0.48	0.27
Pretax Income	-35.14	-41.96	-39.81	-34.55	-24.56
Net Income	-35.14	-41.96	-39.81	-34.55	-24.56
Net Income to Common	-35.14	-41.96	-39.81	-34.55	-24.56
Shares Outstanding (Basic)	76	41	34	34	30
Shares Outstanding (Diluted)	76	41	34	34	30
Shares Change (YoY)	87.22%	18.72%	-	13.05%	53.09%
EPS (Basic)	-0.46	-1.03	-1.16	-1.01	-0.81
EPS (Diluted)	-0.46	-1.03	-1.16	-1.01	-0.81
Free Cash Flow	-43.05	-37.86	-47.92	-40.9	-26.3
Free Cash Flow Per Share	-0.56	-0.93	-1.39	-1.19	-0.86
Gross Margin	15.07%	-34.98%	21.19%	-40.03%	-123.08%
Operating Margin	-324.35%	-382.79%	-293.81%	-562.26%	-557.14%
Profit Margin	-317.62%	-372.04%	-285.28%	-554.72%	-551.21%
Free Cash Flow Margin	-389.04%	-335.70%	-343.41%	-656.63%	-590.41%
EBITDA	-33.37	-42.2	-40.55	-34.57	-24.38
EBITDA Margin	-	-	-290.60%	-	-
D&A For EBITDA	2.52	0.97	0.45	0.46	0.44
EBIT	-35.89	-43.17	-41	-35.02	-24.82
EBIT Margin	-	-	-293.81%	-	-
Revenue as Reported	11.06	11.28	13.96	6.23	4.45

Updated Aug 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.